血清趋化因子配体18在胃癌及癌前病变中的表达意义

Expression of chemokine CC-motif ligand 18 in gastric cancer and precancerous lesions

目的:探讨血清趋化因子配体18(PAFA/CCL18)的含量对胃癌早期诊断的临床应用价值。方法:采用酶联免疫吸附实验(ELISA)检测血清CCL18含量,分析其对胃癌早期诊断的临床应用价值及与胃癌临床生物学行为的关系。结果:CCL18浓度从正常对照组、良性疾病组、胃癌前期病变至胃癌组有升高趋势,除胃癌组(P<0.01)外其他各组间比较差异均无显著性(P>0.05),胃癌患者血清中CCL18的表达水平与肿瘤分化程度、浸润深度、TNM分期和淋巴转移有相关性(P<0.05)。CCL18的胃癌阳性表达率为80.5%。结论:CCL18对胃癌诊断可能有特异性,可作为胃癌早期诊断的标志物。

Objective：To investigate the clinical value of chemokine CC-motif ligand 18（CCL18） in serum for early diagnosis in gastric cancer.Methods：CCL18 in serum was determined by enzyme linked immunosorbent assay（ELISA）.CCL18 was analyzed to judge its early diagnosis value and the relationship with the biology behavior of gastric carcinoma.Results：The level of CCL18 showed the increasing trend from the normal control group,benign diseases group and gastric precancer to gastric cancer group there was no significant difference（P0.05）.Except gastric cancer group,there was no significant difference among the other groups（P0.05）.The expression level of CCL18 was correlated with the degree of differentiation,depth of invasion,TNM stage and lymph node metastasis（P0.05）.The positive expression rate of serum CCL18 was 80.5% in the gastric cancer group.Conclusion：CCL18 may be specific to diagnose gastric cancer,which could be used as the marker for early diagnosis of gastric cancer.